Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Currently amended): An isolated and purified polynuclcotide sequence ~~encoding an immunogenic polypeptide~~ that is a portion of the flaA coding region of Campylobacter, said polynucleotide sequence consisting essentially of nucleotides ~~13–1015~~ 1 – 999 of the DNA SEQ ID NO:1, said polynucleotide encoding an immunogenic polypeptide.

Claim 2 (withdrawn): A recombinant FlaA polypeptide consisting of all or a portion of amino acid sequence SEQ ID NO.:2.

Claim 3 (Currently amended): An isolated and purified DNA sequence encoding an immunogenic polypeptide ~~comprising~~ consisting essentially of amino acid residues ~~5–338~~ 1-333 of amino acid sequence of SEQ ID NO:2.

Claim 4 (Canceled): An expression system consisting of an expression vector wherein the polypeptide of Claim 1 is inserted.

Claim 5 (Canceled): The expression system of Claim 4 wherein the expression vector is selected from the group consisting of plasmid and viral and E.coli expression vectors.

Claim 6 (Canceled): An expression system of Claim 5 wherein the plasmid vector is selected from the group consisting of pMal-c2, pMal-p2 and pET.

Claim 7 (Canceled): An expression system of Claim 4 wherein the viral expressin vector of Claim 5 is selected from the group consisting of adenovirus, M13, herpesvirus, vaccinia virus and baculovirus.

Claim 8 (Withdrawn): A method for inducing an immune response to FlaA comprising administering the polypeptide of Claim 2 to a subject.

Claim 9 (Withdrawn): The method of Claim 8 wherein the polypeptide is administered in conjunction with other known vaccines to form a multivalent formulation.

Claim 10 (Withdrawn): The method of Claim 8 wherein the polypeptide is administered as an injectable formulation.

Claim 11 (Withdrawn): The method of Claim 8 wherein the polypeptide is adminstered as an intranasal formulation.

Claim 12 (Withdrawn): The method of Claim 8 wherein the polypeptide is administered as an oral formulation.

Claim 13 (Withdrawn): The method of Claim 8 wherein administering the polypeptide to subjects has no or reduced ability to induce GBS.

Claim 14 (Withdrawn): A method of reducing campylobacter intestinal colonization in a subject, said method comprising administering an immunogenically effective amount of MBP-FlaA with or without an adjuvant.

Claim 15 (Withdrawn): A method of reducing campylobacter intestinal colonization in a subject, said method comprising administering an immunogenically effective amount of MBP-FlaA + LT_{R192G}.

Claim 16 (Currently amended) The polynucleotide sequence of Claim 1, wherein said sequence is expressed in an ~~suitable~~ expression system comprising a DNA expression vector selected from the group consisting of plasmid, viral and E. coli expression vectors.

Claim 17 (New): The polynucleotide sequence of Claim 16, wherein said expression system comprises an E. coli gene encoding maltose binding protein, said polynucleotide sequence being fused to said gene and said gene being contained in an expression vector.

Claim 18 (New) An immunogenic composition comprising:

an isolated and purified polynucleotide sequence consisting essentially of nucleotides 1- 999 of SEQ ID NO. 1 encoding an immunogenic polypeptide consisting essentially of amino acid residues 1 - 333 of SEQ ID NO. 2; and

an expression system selected from the group consisting of plasmid, viral and E. coli expression vectors.

Claim 19 (New): The immunogenic composition of Claim 18, wherein said expression system comprises an E. coli gene encoding maltose binding protein, said polynucleotide sequence being fused to said gene and said gene being contained in an expression vector.

Claim 20 (New): The immunogenic composition of Claim 19, further comprising an adjuvant.

Claim 21 (New): The immunogenic composition of Claim 20, wherein said adjuvant is a non-toxigenic form of heat labile E. coli enterotoxin.

Claim 22 (New) A bivalent immunogenic composition comprising:
an isolated and purified polynucleotide sequence consisting essentially of nucleotides 1 - 999 of SEQ ID NO. 1 encoding an immunogenic polypeptide consisting essentially of amino acid residues 1 - 333 of SEQ ID NO.2;

an expression system selected from the group consisting of plasmid, viral and E. coli expression vectors; and

a carrier strain consisting of live, attenuated bacteria wherein said bacteria is modified to express said polynucleotide sequence encoding said polypeptide.

Claim 23 (New): The bivalent immunogenic composition of Claim 22, wherein said expression system comprises an E. coli gene encoding maltose binding protein, said

polynucleotide sequence being fused to said gene and said gene being contained in an expression vector.

Claim 24 (New): The bivalent immunogenic composition of Claim 22, wherein said carrier strain comprises Salmonella or Shigella.

Claim 25 (New): The polynucleotide sequence of Claim 1 encoding said immunogenic polypeptide that has reduced or no induction of Guillain-Barre Syndrome.

Claim 26 (New): The immunogenic polypeptide of Claim 3 that has reduced or no induction of Guillain-Barre Syndrome.

Claim 27 (New): The isolated and purified polynucleotide sequence of Claim 16, wherein said sequence is useful in reducing colonization of Campylobacter.

Claim 28 (New): The isolated and purified DNA sequence of Claim 3, wherein said encoded polypeptide is useful in reducing colonization of Campylobacter.